Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC9204-0530 + Liraglutide in Overweight/Obesity
NCT02870231Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2016
- Primary completion
- Sep 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC9204-0530 in obesity and Overweight (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Started Aug 2016; status: completed.
02
Drugs
NNC9204-0530
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT02870231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870231.